[go: up one dir, main page]

DZ3315A1 - Formulations pharmaceutiques pour inhalateurs de poudre seche sous forme de pastilles dures - Google Patents

Formulations pharmaceutiques pour inhalateurs de poudre seche sous forme de pastilles dures

Info

Publication number
DZ3315A1
DZ3315A1 DZ013315A DZ013315A DZ3315A1 DZ 3315 A1 DZ3315 A1 DZ 3315A1 DZ 013315 A DZ013315 A DZ 013315A DZ 013315 A DZ013315 A DZ 013315A DZ 3315 A1 DZ3315 A1 DZ 3315A1
Authority
DZ
Algeria
Prior art keywords
dry powder
fraction
powder
pellets
hard
Prior art date
Application number
DZ013315A
Other languages
English (en)
Inventor
John Nicholas Staniforth
David Alexander Vodden Morton
Rajbir Gill
Gaetano Brambilla
Rossella Musa
Lorenzo Ferrarini
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ3315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0009469.8A external-priority patent/GB0009469D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Application granted granted Critical
Publication of DZ3315A1 publication Critical patent/DZ3315A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DZ013315A 2000-04-17 2001-04-17 Formulations pharmaceutiques pour inhalateurs de poudre seche sous forme de pastilles dures DZ3315A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0009469.8A GB0009469D0 (en) 2000-04-17 2000-04-17 Improvements in or relating to formalities for use in inhaler devices
EP00113608 2000-06-27
PCT/EP2001/004338 WO2001078693A2 (fr) 2000-04-17 2001-04-17 Formulations pharmaceutiques pour inhalateurs de poudre seche sous forme de pastilles dures

Publications (1)

Publication Number Publication Date
DZ3315A1 true DZ3315A1 (fr) 2001-10-25

Family

ID=26071084

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013315A DZ3315A1 (fr) 2000-04-17 2001-04-17 Formulations pharmaceutiques pour inhalateurs de poudre seche sous forme de pastilles dures

Country Status (32)

Country Link
US (4) US8182791B2 (fr)
EP (6) EP1276473B1 (fr)
JP (2) JP2003530425A (fr)
KR (1) KR20030069047A (fr)
CN (1) CN1424909A (fr)
AT (5) ATE377416T1 (fr)
AU (3) AU784719B2 (fr)
BR (3) BR0110139A (fr)
CA (3) CA2406201C (fr)
CY (1) CY1107315T1 (fr)
CZ (1) CZ301904B6 (fr)
DE (3) DE60123031T2 (fr)
DK (3) DK1274406T3 (fr)
DZ (1) DZ3315A1 (fr)
EE (1) EE05257B1 (fr)
ES (3) ES2275669T3 (fr)
GB (2) GB2363987A (fr)
HU (4) HU229270B1 (fr)
IL (1) IL152306A0 (fr)
MA (1) MA26892A1 (fr)
MX (3) MXPA02010218A (fr)
MY (1) MY129384A (fr)
NO (4) NO332025B1 (fr)
NZ (1) NZ521887A (fr)
PE (1) PE20011227A1 (fr)
PL (3) PL204213B1 (fr)
PT (3) PT1276472E (fr)
SA (1) SA01220062B1 (fr)
SI (2) SI1719505T1 (fr)
SK (1) SK284248B6 (fr)
TN (1) TNSN01060A1 (fr)
WO (3) WO2001078694A2 (fr)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
DK1158958T3 (da) * 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US7744855B2 (en) * 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
NZ526059A (en) † 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
AU2002220857A1 (en) 2000-11-30 2002-06-11 Vectura Limited Particles for use in a pharmaceutical composition
ATE382335T1 (de) * 2000-11-30 2008-01-15 Vectura Ltd Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
WO2002056948A1 (fr) 2001-01-17 2002-07-25 Vectura Limited Dispositif d'inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003024396A2 (fr) 2001-09-17 2003-03-27 Glaxo Group Limited Formulations de medicament en poudre seche
US7931533B2 (en) 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
EP1498116A1 (fr) * 2002-03-20 2005-01-19 Hosokawa Micron Corporation Procede de fabrication de particules composites contenant un produit chimique
FI116657B (fi) * 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
US20030235538A1 (en) * 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1599209B1 (fr) * 2002-08-21 2011-08-17 Norton Healthcare Limited Compositions a inhaler
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1452179A1 (fr) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
WO2004093848A2 (fr) * 2003-04-14 2004-11-04 Vectura Ltd Dispositifs et compositions pharmaceutiques destines a ameliorer l'efficacite de dosage
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US7094545B2 (en) * 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
EP1646370A1 (fr) * 2003-07-11 2006-04-19 Glaxo Group Limited Formulations pharmaceutiques
SI1500390T1 (sl) 2003-07-25 2006-02-28 Ferring Bv Farmacevtski dezmopresinski sestavek kot trdna dozirna oblika in postopek za njegovo pripravo
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
WO2005025535A2 (fr) * 2003-09-15 2005-03-24 Vectura Limited Procedes de preparation de compositions pharmaceutiques
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2547782A1 (fr) * 2003-12-03 2005-06-16 Microdrug Ag Produit medical contenant du tiotropium
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303569L (sv) * 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
KR101725225B1 (ko) 2004-04-23 2017-04-12 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
CN101155590A (zh) 2005-02-10 2008-04-02 葛兰素集团有限公司 使用预分选技术制备乳糖的方法以及由此形成的药物制剂
JPWO2006095788A1 (ja) * 2005-03-09 2008-08-14 小野薬品工業株式会社 粒子およびその粒子を含有する製剤
WO2006105401A2 (fr) * 2005-03-30 2006-10-05 Schering Corporation Medicaments et procedes de combinaison d'un anticholinergique, un corticosteroide, et un agoniste beta a action prolongee
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP1944018A1 (fr) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation
EP2425820B1 (fr) 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Procédé pour l'administration thérapeutique de DHE pour soulager rapidement la migraine tout en diminuant son profil d'effets secondaires
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
JP5240205B2 (ja) 2008-01-11 2013-07-17 アステラス製薬株式会社 精巣の疼痛又は不快感行動及び頻尿併発モデル動物
EP2080508A1 (fr) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Formulation de poudre sèche comprenant un médicament anticholinérgique
WO2010059836A1 (fr) 2008-11-20 2010-05-27 Decode Genetics Ehf Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
EP2191821A1 (fr) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles contenant une sel de 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone avec adhesion ameliorée pour l'inhalation de poudre sèche
JP5874878B2 (ja) 2009-01-26 2016-03-02 イスラエル インスティトゥート フォー バイオロジカル リサーチ 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010097188A1 (fr) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
SI2400950T1 (sl) 2009-02-26 2019-09-30 Glaxo Group Limited Farmacevtske forlmulacije, ki obsegajo 4-((1 R)-2-((6-(2-((2,6- diklorobenzil)oksi)etoksi)heksil)amino)-1-hidroksietil)-2- (hidroksimetil)fenol
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
WO2011015289A1 (fr) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. Hémi-fumarate de 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2- (4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1h)-quinolinone
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2360147A1 (fr) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Procédé de préparation de particules crystallines d'un sel de 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
MX336414B (es) 2010-04-01 2016-01-19 Chiesi Farma Spa Proceso de preparacion de particulas portadoras para polvos secos para inhalacion.
AU2011244384B2 (en) * 2010-04-21 2016-06-23 Chiesi Farmaceutici S.P.A. "Process for providing particles with reduced electrostatic charges"
EA028899B1 (ru) 2010-04-30 2018-01-31 Алексион Фармасьютикалз, Инк. АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
EP2575786B1 (fr) 2010-06-03 2017-11-15 Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. Procédé pour formulations pulvérulentes sèches
AU2011269238A1 (en) 2010-06-22 2013-01-10 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
MX346424B (es) 2010-08-03 2017-03-21 Chiesi Farm Spa Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa.
WO2012028745A1 (fr) * 2010-09-03 2012-03-08 Pharmaterials Limited Composition pharmaceutique adaptée pour une utilisation dans un inhalateur de poudre sèche
EP2621484A1 (fr) 2010-09-29 2013-08-07 Pulmatrix, Inc. Poudres sèches à cations métalliques monovalents pour inhalation
RU2580890C2 (ru) 2010-09-30 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Применение стеарата магния в составах сухого порошка для ингаляции
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
EP2804583A1 (fr) * 2012-01-16 2014-11-26 Mahmut Bilgic Formulations en poudre sèche comprenant du r-formotérol utilisé comme agent actif
WO2013109214A1 (fr) * 2012-01-16 2013-07-25 Mahmut Bilgic Procédé de préparation de formulations en poudre sèche
WO2013109215A1 (fr) * 2012-01-16 2013-07-25 Mahmut Bilgic Préparation de formulations en poudre sèche comprenant du formotérol
PL3412277T3 (pl) 2012-01-25 2023-06-19 Chiesi Farmaceutici S.P.A. Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
EP2819672A1 (fr) 2012-02-29 2015-01-07 Pulmatrix, Inc. Poudres sèches pouvant être inhalées
WO2013132498A2 (fr) 2012-03-07 2013-09-12 Advanced Inhilation Therapies (Ait) Ltd. Inhalation d'oxyde nitrique pour traiter des maladies respiratoires
AU2013234080B2 (en) 2012-03-13 2016-12-22 Respivert Limited Novel pharmaceutical formulations
EP2836204B1 (fr) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Particules agrégées
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US11052202B2 (en) 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CA2897464C (fr) 2013-01-28 2021-05-18 Incozen Therapeutics Pvt. Ltd. Procedes de traitement de troubles auto-immuns, respiratoires et inflammatoires par inhalation de n-oxyde de roflumilast
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
PL2821061T3 (pl) * 2013-07-01 2018-05-30 Arven Ilac Sanayi Ve Ticaret A.S. Nowe preparaty do inhalacji
US9402825B2 (en) * 2013-07-11 2016-08-02 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
US20160235667A1 (en) * 2013-10-02 2016-08-18 Vectura Limited Method and apparatus for making compositions for pulmonary administration
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
EP2957552B1 (fr) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Formulations de vilanterol
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
ES2701525T3 (es) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
EP3212212B1 (fr) 2014-10-31 2020-09-23 Monash University Formulation de poudre
US10655408B2 (en) * 2015-06-23 2020-05-19 Schlumberger Technology Corporation Mobile proppant recognition
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
UA125173C2 (uk) * 2015-11-16 2022-01-26 Кьєзі Фармачеутічі С.П.А. Спосіб одержання сухої порошкової композиції, що містить антихолінергічний засіб, кортикостероїд і бета-адренергічний засіб
MY186229A (en) 2015-11-16 2021-06-30 Chiesi Farm Spa A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
KR102697599B1 (ko) 2015-12-24 2024-08-23 필립모리스 프로덕츠 에스.에이. 니코틴 입자 캡슐
EP3909609A1 (fr) 2016-05-27 2021-11-17 Alexion Pharmaceuticals, Inc. Procédés de traitement de la myasthénie grave généralisée réfractaire
WO2018045217A1 (fr) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglies dans la neuro-inflammation associée aux maladies neurodégénératives
KR20240105510A (ko) * 2017-05-11 2024-07-05 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
KR102637303B1 (ko) 2017-05-11 2024-02-20 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
SG11202000105QA (en) 2017-07-14 2020-02-27 Cytomx Therapeutics Inc Anti-cd166 antibodies and uses thereof
CN111107788B (zh) * 2017-07-26 2023-12-19 深圳帧观德芯科技有限公司 具有空间扩展性x射线源的x射线成像系统
CN111315411B (zh) 2017-07-27 2023-02-28 瑞颂医药公司 高浓度抗c5抗体制剂
WO2019060604A1 (fr) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. Médicament inhalable
CN115919780A (zh) * 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019060797A1 (fr) 2017-09-22 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. Procédé de fabrication de poudres à inhaler
WO2019067708A1 (fr) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. Procédé pour diminuer la taille de particules
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
WO2019231983A1 (fr) 2018-05-31 2019-12-05 Alexion Pharmaceuticals, Inc. Dosage et administration d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh) chez des patients pédiatriques
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
AU2019299347A1 (en) * 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
KR102784384B1 (ko) 2018-07-27 2025-03-21 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제를 위한 신규 담체 입자
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
MX2021004994A (es) 2018-10-30 2021-06-15 Alexion Pharma Inc Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
KR102778714B1 (ko) 2018-10-30 2025-03-10 치에시 파마슈티시 에스.피.아. 기계 호흡중인 환자에게 약물을 투여하는 장치
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
CN120005921A (zh) 2018-12-12 2025-05-16 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
WO2020223237A1 (fr) 2019-04-29 2020-11-05 Insmed Incorporated Compositions de poudre sèche de promédicaments de tréprostinil et méthodes d'utilisation de celles-ci
CN114514020A (zh) 2019-09-24 2022-05-17 奇斯药制品公司 用于吸入用干粉制剂的新型载体颗粒
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
BR112022021450A2 (pt) 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
WO2021237109A1 (fr) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Polythérapie pour le traitement d'infections virales
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
EP4320149A1 (fr) 2021-04-09 2024-02-14 Takeda Pharmaceutical Company Limited Anticorps ciblant le facteur d du complément et leurs utilisations
PH12023552669A1 (en) 2021-04-26 2024-02-19 Millennium Pharm Inc Anti-clec12a antibodies and uses thereof
BR112023020371A2 (pt) 2021-04-26 2024-02-06 Millennium Pharm Inc Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer
EP4419561A2 (fr) 2021-10-20 2024-08-28 Takeda Pharmaceutical Company Limited Compositions ciblant bcma et leurs procédés d'utilisation
WO2023117967A1 (fr) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Formulations en poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023150747A1 (fr) 2022-02-07 2023-08-10 Insmed Incorporated Compositions de poudre sèche de bédaquiline et de sels et leurs méthodes d'utilisation
JP2025532672A (ja) 2022-09-22 2025-10-01 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホスホジエステラーゼ－４阻害剤の投与のためのカプセル吸入器

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1571629A (en) 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
ES2044710T3 (es) 1990-01-29 1994-01-01 Ciba Geigy Ag Procedimiento y dispositivo de dosificacion de un polvo de granulometria fina.
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
KR100208979B1 (ko) 1992-06-12 1999-07-15 야스이 쇼사꾸 기도내 투여용 제제
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9700136D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CA2305260A1 (fr) * 1997-09-30 1999-04-08 Mortimer Technology Holdings Limited Procede et appareil de traitement de matieres particulaires
US6655379B2 (en) * 1998-03-16 2003-12-02 Nektar Therapeutics Aerosolized active agent delivery
DE59914603D1 (de) 1998-11-13 2008-02-14 Jagotec Ag Multidosis-Trockenpulverinhalator mit Pulverreservoir
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
DK1158958T3 (da) 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
KR100702878B1 (ko) * 1999-10-29 2007-04-04 넥타르 테라퓨틱스 개선된 분산성을 갖는 건조 분말 조성물
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US7744855B2 (en) * 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition

Also Published As

Publication number Publication date
GB0109431D0 (en) 2001-06-06
NO336687B1 (no) 2015-10-19
KR20030069047A (ko) 2003-08-25
GB2363988A (en) 2002-01-16
EP2272508A3 (fr) 2012-01-18
HUP0300499A2 (en) 2003-07-28
EP1276472B1 (fr) 2006-12-20
PT1719505E (pt) 2011-10-24
NO20024971D0 (no) 2002-10-16
EE200200593A (et) 2004-04-15
NO20024980L (no) 2002-12-17
PE20011227A1 (es) 2002-01-07
AU4858101A (en) 2001-10-30
NO20024973L (no) 2002-12-16
NO20024980D0 (no) 2002-10-16
GB0109432D0 (en) 2001-06-06
US7223748B2 (en) 2007-05-29
HUP0300593A2 (hu) 2003-09-29
DK1276472T3 (da) 2007-04-16
EP1719505A2 (fr) 2006-11-08
EP1276473A2 (fr) 2003-01-22
PL204213B1 (pl) 2009-12-31
PL204251B1 (pl) 2009-12-31
NO20024971L (no) 2002-12-17
ATE513542T1 (de) 2011-07-15
WO2001078693A2 (fr) 2001-10-25
EP1719505B1 (fr) 2011-08-24
CA2405767A1 (fr) 2001-10-25
AU4859501A (en) 2001-10-30
IL152306A0 (en) 2003-05-29
MXPA02010213A (es) 2005-07-01
TNSN01060A1 (fr) 2005-11-10
CA2406201C (fr) 2011-03-22
WO2001078694A2 (fr) 2001-10-25
ATE377416T1 (de) 2007-11-15
ES2275669T3 (es) 2007-06-16
EP1276473B1 (fr) 2007-11-07
CY1107315T1 (el) 2012-11-21
EP1829533A3 (fr) 2007-10-31
CA2406119A1 (fr) 2001-10-25
ATE521340T1 (de) 2011-09-15
BR0110141A (pt) 2003-01-28
HUP1300117A2 (en) 2003-07-28
ATE348603T1 (de) 2007-01-15
EE05257B1 (et) 2010-02-15
NO20110885L (no) 2002-12-17
BR0110139A (pt) 2002-12-31
NO20024973D0 (no) 2002-10-16
US8182791B2 (en) 2012-05-22
WO2001078694A3 (fr) 2002-03-14
DE60123031T2 (de) 2007-03-08
EP2272508A2 (fr) 2011-01-12
DK1274406T3 (da) 2007-01-22
HU230464B1 (hu) 2016-07-28
ES2292576T3 (es) 2008-03-16
DE60123031D1 (de) 2006-10-26
NO342999B1 (no) 2018-09-24
CN1424909A (zh) 2003-06-18
EP2272508B1 (fr) 2020-03-25
MXPA02010218A (es) 2003-05-23
WO2001078693A3 (fr) 2002-01-17
US20050201950A1 (en) 2005-09-15
CA2406201A1 (fr) 2001-10-25
PL358875A1 (en) 2004-08-23
PT1274406E (pt) 2007-01-31
SA01220062B1 (ar) 2006-11-05
EP1274406B1 (fr) 2006-09-13
SI1274406T1 (sl) 2007-02-28
MY129384A (en) 2007-03-30
WO2001078695A2 (fr) 2001-10-25
HUP0300490A2 (en) 2003-07-28
EP1829533A2 (fr) 2007-09-05
US20030180227A1 (en) 2003-09-25
SK14912002A3 (sk) 2003-03-04
MA26892A1 (fr) 2004-12-20
HU229270B1 (en) 2013-10-28
BR0110301A (pt) 2003-12-30
DE60125344T2 (de) 2007-07-19
ATE339195T1 (de) 2006-10-15
EP1276472A2 (fr) 2003-01-22
PT1276472E (pt) 2007-02-28
PL359289A1 (en) 2004-08-23
HUP0300593A3 (en) 2006-07-28
EP1719505A3 (fr) 2007-07-18
AU2001258343A1 (en) 2001-10-30
JP2012255035A (ja) 2012-12-27
SK284248B6 (sk) 2004-12-01
SI1719505T1 (sl) 2011-12-30
EP1829533B1 (fr) 2011-06-22
NZ521887A (en) 2004-06-25
MXPA02010212A (es) 2004-06-29
DE60131265T2 (de) 2008-03-06
HU229797B1 (en) 2014-07-28
US6884794B2 (en) 2005-04-26
WO2001078695A3 (fr) 2002-03-14
EP1274406A2 (fr) 2003-01-15
DE60131265D1 (de) 2007-12-20
CZ20023437A3 (cs) 2003-02-12
AU784719B2 (en) 2006-06-01
CA2406119C (fr) 2009-07-07
CA2405767C (fr) 2011-07-05
US20120308613A1 (en) 2012-12-06
CZ301904B6 (cs) 2010-07-28
PL358640A1 (en) 2004-08-09
GB2363987A (en) 2002-01-16
JP2003530425A (ja) 2003-10-14
ES2272473T3 (es) 2007-05-01
DK1719505T3 (da) 2011-12-05
US20030175214A1 (en) 2003-09-18
NO332025B1 (no) 2012-05-29
DE60125344D1 (de) 2007-02-01

Similar Documents

Publication Publication Date Title
DZ3315A1 (fr) Formulations pharmaceutiques pour inhalateurs de poudre seche sous forme de pastilles dures
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
US6503481B1 (en) Compositions for aerosolization and inhalation
JO3102B1 (ar) صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
HU220290B (hu) Inhaláló készülék és eljárás száraz por alakú aktív anyag inhalálására
JP2001527442A (ja) ハロセラピーの投与方法
AP2002002623A0 (en) Use of compounds in a dry powder inhaler
JP2002161030A (ja) 異なる粒径をもった混合粉体の吸入方法
AU2004235631A1 (en) Compositions for aerosolization an inhalation